Today, Jamie Murray commented about whether STLC-T, STZ-N, MSFT-Q, CBD-T, HD-N, WCP-T, ATVI-Q, INTC-Q, AVGO-Q, RCL-N, TFX-N, RDS.A-N, DIS-N, T-N, NFI-T, MFC-T, CIGI-T, KXS-T, PEP-Q, WPK-T, RDS.A-N, VET-T, TD-T, LULU-Q are stocks to buy or sell.
After NAFTA's resolution yesterday there are more opportunities. He likes the auto sector (cash flow, valuations) for a rebound trade. Also likes Saputo, which could see some strength. Outsiders may invest in Canada again. The LNG announcement may signal to the world that we can get things done in Canada; it's positive. Investors want to see resolution to TransMountain though. The housing market could be a Canadian headwind in the next few years. He's always been overweight U.S. stocks where the economy is strong, and he still sees more rebound in that economy.
A great performer this year. They've done a nice job with their product line and hitting on the fashion trends. Selling online has seen massive growth. It trades at 40x earnings (historical earnings are 32x). They've had missteps in the past five years, though. He's waiting for a better entry point. He's also looking at Aritzia in the clothing space.
A core holding. Shares haven't done much over the past two years. Rising interest rates will kick some life into insurance stocks. MFC needs to sort out its John Hancock division in the U.S. Its Asian franchise is the crown jewel, though, so as this franchise grows, so will this stock. MFC has a strong presence in Asia where insurance is not saturated like it is in North America.
He prefers BP which has better upside. RDS though has a nice cash flow and did a great job repositioned the company on the downstream side. Has one of the lowest-cost asset bases. Pays over a 5% dividend. The LNG project in BC announced today will impact RDS who are one of the investors/partners, but there's a real risk of huge cost overruns.
(Past Top Pick May 4, 2018, Down 2%) It pulled back heavily after August earnings. There were concerns over legacy products lines and weak organic growth. He used that pullback to double his position. Still likes it. There's margin expansion as they consolidate their manufacturing operation. They have high-growth product lines with EPS growth at 15%. He really likes the medical products space because of the aging population.